Literature DB >> 22541282

Rapid point-of-care NT-proBNP optimal cut-off point for heart failure diagnosis in primary care.

José M Verdú1, Josep Comín-Colet, Mar Domingo, Josep Lupón, Miguel Gómez, Luis Molina, Jose M Casacuberta, Miguel A Muñoz, Amparo Mena, Jordi Bruguera-Cortada.   

Abstract

INTRODUCTION AND
OBJECTIVES: Measurement of natriuretic peptides may be recommended prior to echocardiography in patients with suspected heart failure. Cut-off point for heart failure diagnosis in primary care is not well established. We aimed to assess the optimal diagnostic cut-off value of N-terminal pro-B-type natriuretic peptide on a community population attended in primary care.
METHODS: Prospective diagnostic accuracy study of a rapid point-of-care N-terminal pro-B-type natriuretic peptide test in a primary healthcare centre. Consecutive patients referred by their general practitioners to echocardiography due to suspected heart failure were included. Clinical history and physical examination based on Framingham criteria, electrocardiogram, chest X-ray, N-terminal pro-B-type natriuretic peptide measurement and echocardiogram were performed. Heart failure diagnosis was made by a cardiologist blinded to N-terminal pro-B-type natriuretic peptide value, using the European Society of Cardiology diagnosis criteria (clinical and echocardiographic data).
RESULTS: Of 220 patients evaluated (65.5% women; median 74 years [interquartile range 67-81]). Heart failure diagnosis was confirmed in 52 patients (23.6%), 16 (30.8%) with left ventricular ejection fraction <50% (39.6 [5.1]%). Median values of N-terminal pro-B-type natriuretic peptide were 715 pg/mL [interquartile range 510.5-1575] and 77.5 pg/mL [interquartile range 58-179.75] for patients with and without heart failure respectively. The best cut-off point was 280 pg/mL, with a receiver operating characteristic curve of 0.94 (95% confidence interval, 0.91-0.97). Six patients with heart failure diagnosis (11.5%) had N-terminal pro-B-type natriuretic peptide values <400 pg/mL. Measurement of natriuretic peptides would avoid 67% of requested echocardiograms.
CONCLUSIONS: In a community population attended in primary care, the best cut-off point of N-terminal pro-B-type natriuretic peptide to rule out heart failure was 280 pg/mL. N-terminal pro-B-type natriuretic peptide measurement improve work-out diagnoses and could be cost-effectiveness.
Copyright © 2012 Sociedad Española de Cardiología. Published by Elsevier Espana. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22541282     DOI: 10.1016/j.recesp.2012.01.019

Source DB:  PubMed          Journal:  Rev Esp Cardiol (Engl Ed)        ISSN: 1885-5857


  9 in total

Review 1.  Diagnostic point-of-care tests in resource-limited settings.

Authors:  Paul K Drain; Emily P Hyle; Farzad Noubary; Kenneth A Freedberg; Douglas Wilson; William R Bishai; William Rodriguez; Ingrid V Bassett
Journal:  Lancet Infect Dis       Date:  2013-12-10       Impact factor: 25.071

2.  Real-World Epidemiology of Potassium Derangements Among Chronic Cardiovascular, Metabolic and Renal Conditions: A Population-Based Analysis.

Authors:  Santiago Jiménez-Marrero; Miguel Cainzos-Achirica; David Monterde; Luis Garcia-Eroles; Cristina Enjuanes; Sergi Yun; Alberto Garay; Pedro Moliner; Lidia Alcoberro; Xavier Corbella; Josep Comin-Colet
Journal:  Clin Epidemiol       Date:  2020-09-11       Impact factor: 4.790

Review 3.  Point-of-care testing of (N-terminal pro) B-type natriuretic peptide for heart disease patients in home care and ambulatory care settings.

Authors:  Nayuta Shimizu; Kazuhiko Kotani
Journal:  Pract Lab Med       Date:  2020-10-17

4.  Diagnosing heart failure in primary care: individual patient data meta-analysis of two European prospective studies.

Authors:  Andrea K Roalfe; Clare J Taylor; Johannes C Kelder; Arno W Hoes; F D Richard Hobbs
Journal:  ESC Heart Fail       Date:  2021-03-23

5.  Validation of heart failure diagnosis registered in primary care records in two primary care centres in Barcelona (Spain) and factors related. A cross-sectional study.

Authors:  Jose María Verdú-Rotellar; Eva Frigola-Capell; Rosa Alvarez-Pérez; Daniela da Silva; Cristina Enjuanes; Mar Domingo; Amparo Mena; Miguel-Angel Muñoz
Journal:  Eur J Gen Pract       Date:  2017-12       Impact factor: 1.904

Review 6.  Diagnostic accuracy of point-of-care natriuretic peptide testing for chronic heart failure in ambulatory care: systematic review and meta-analysis.

Authors:  Kathryn S Taylor; Jan Y Verbakel; Benjamin G Feakins; Christopher P Price; Rafael Perera; Clare Bankhead; Annette Plüddemann
Journal:  BMJ       Date:  2018-05-21

7.  Gene expression profiling of hypertrophic cardiomyocytes identifies new players in pathological remodelling.

Authors:  Marta Vigil-Garcia; Charlotte J Demkes; Joep E C Eding; Danielle Versteeg; Hesther de Ruiter; Ilaria Perini; Lieneke Kooijman; Monika M Gladka; Folkert W Asselbergs; Aryan Vink; Magdalena Harakalova; Alexander Bossu; Toon A B van Veen; Cornelis J Boogerd; Eva van Rooij
Journal:  Cardiovasc Res       Date:  2021-05-25       Impact factor: 10.787

8.  Assessment of the impact of different N terminal pro brain natriuretic peptide thresholds on echocardiography services.

Authors:  Eric Yii; Omar Fersia; Angus McFadyen; Christopher Isles
Journal:  ESC Heart Fail       Date:  2021-12-08

9.  NT-ProBNP and high-sensitivity troponin T as screening tests for subclinical chronic heart failure in a general population.

Authors:  Maria Averina; Michael Stylidis; Jan Brox; Henrik Schirmer
Journal:  ESC Heart Fail       Date:  2022-03-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.